MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2015

TABLE OF CONTENTS

PIVOTAL THERAPEUTICS INC.
(A Development Stage Company)

MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2015

DATE AND SUBJECT OF REPORT

The following Management's Discussion and Analysis ("**MD&A**") of the financial condition and results of operations for Pivotal Therapeutics Inc. (the "**Company**" or "**Pivotal**") is intended to assist in the understanding of the trends and significant changes in the financial condition and results of operations of the Company for the three and six months ended June 30, 2015, which have been prepared in accordance with International Financial Reporting Standards ("**IFRS**"). The MD&A should be read in conjunction with the audited financial statements and notes thereto for the period ended December 31, 2014. The MD&A has been prepared effective August 28, 2015. All amounts are expressed in Canadian dollars unless otherwise indicated.

FORWARD-LOOKING STATEMENTS

The information set forth in this MD&A contains statements concerning future results, future performance, intentions, objectives, plans and expectations that are, or may be deemed to be, forward-looking statements. These statements concerning possible or assumed future results of operations of the Company are preceded by, followed by or include the words 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'forecasts,' or similar expressions. Forward-looking statements are not guarantees of future performance. These forward-looking statements are based on current expectations that involve numerous risks and uncertainties, including but not limited to, those identified in the Risks Factors section. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. These factors should be considered carefully, and readers should not place undue reliance on forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether written or oral that may be made by or on the Company's behalf.

Further information is available on the SEDAR website, www.sedar.com.

BUSINESS OVERVIEW

GENERAL AND BUSINESS DEVELOPMENT

The Company is a specialty pharmaceutical company with expertise in cardiovascular science, focused on cardiovascular disease and overall health. Pivotal's lead prescription-only medical food product, VASCAZEN®, is used for the clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, Eicosapentaenoic Acid ("**EPA**") and Docosahexanenoic Acid ("**DHA**") levels. VASCAZEN® is a unique pharmaceutical formulation of EPA:DHA and provides the cornerstone upon which a family of combination products, having efficacy across a broad spectrum of cardiac indications, will be developed, and for which the Company is developing a substantial Intellectual Property portfolio. The Company's strategy is centered on cardio-protection that is administered and overseen by a physician. The Company is commercializing VASCAZEN® as a medical food through physician prescription and in combination with a unique monitoring strategy. Based on the Senior Managements internal strengths and track record, the Company is developing a unique rapid format diagnostic test for Omega-3 deficiency.

The Company's operational concept and approach is to participate in areas where it can best create and capture value while minimizing risk. The Company's operational concept and organizational structure was designed to avoid the more costly and asset intensive aspects of the traditional pharmaceutical industry.

At present the Company is funding the following activities through the issuance of securities, including common shares and debt financing:

- Increasing the selling and marketing of VASCAZEN® into the North American and International market place;
- Expansion of the VASCAZEN® distribution network worldwide;
- Pursuing co-marketing medical food partnership to increase sales footprint and conversion of current sales force to mainly commissioned-based;
- Prosecution and issuance of U.S. and international patent applications;
- Expansion of intellectual property patent portfolio;
- Strategic clinical marketing and registration trials;
- Pursuing licensing opportunities for our unique patented 6:1 EPA:DHA formulation in North America, Europe, East Asia, China and Korea;
- Conducting research and development activities to expand the indication for our unique patented 6:1 EPA: DHA formulation;
- Pivotal introduced PVT-100 as its first drug candidate. PVT-100's indication is for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. The development of PVT-100 is connected to the successful execution of the Company's POMEGA Phase IIa clinical trial. Patient enrollment for the trial commenced in the first half of 2015;

- Developing diagnostic reagents and rapid format tests for the identification of Omega-3 deficiency in patients;
- Introducing Benefishial™ to the over-the-counter (OTC) marketplace and direct to consumer by positioning it for major drugstore chains in the U.S. and Canada;
- Publication of scientific data validating the efficacy of products and expansion of new indications;
- Ongoing investor presentation and promotion in the interest of broadening the Company's shareholder base in North America and in Europe.

Listing

The Company trades on the Canadian Securities Exchange ("**CSE**" formerly "**CNSX**") under the symbol PVO and trades on the U.S. exchange, OTC Markets QX ("**OTCQX**") under the symbol PVTTF.

CORPORATE UPDATE

The Company achieved the following milestones between January 1, 2015 and the date of this report, as set out in the following announcements:

- January 22, 2015 – the Company published its CEO update and 2014 year in review;
- January 27, 2015 – the Company announced receiving final approval for the Phase IIa POMEGA clinical trial;
- February 10, 2015 – the Company announced the issuance of two patents, both related to the combination of VASCAZEN® with key cholesterol lowering agents (statins) and cholesterol absorption inhibitors;
- April 1, 2015 – the Company announced having received a notice of allowance for U.S. Patent related to a kit for the dietary management of cardiovascular patients that includes VASCAZEN® and an Omega -3 fatty acid diagnostic assay;
- April 15, 2015 – the Company announced having executed a memorandum of understanding with Korea Animal Medical Science Institute ("**KAMSI**") and its newly created affiliate for the exclusive sales and distribution of the Benefishial™ family of products;
- April 27, 2015 – the Company announced having received Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support cardiovascular health and normal triglyceride levels;
- April 30, 2015 – the Company announced its 2014 financial results;
- June 1, 2015 – the Company announced its First Quarter 2015 financial results;
- June 4, 2015 – the Company announced the first patient enrolled in it's POMEGA Phase IIa clinical trial with PVT-100;
- June 29, 2015 – the Company announced that it proposes to raise up to $1,540,000 through a non-brokered private placement.

BUSINESS INITIATIVES

The following is a brief description of the business initiatives that are currently underway.

The Company continues to make efforts to expand its product lines. The current product portfolio consists of three product lines; (i) VASCAZEN® is currently sold in the United States (**"U.S."**) as a prescription-only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease, (ii) OMAZEN® is being commercialized in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels and (iii) Benefishial™, which is targeting the direct to consumer market place and consists of six different products.

During 2014 Pivotal had begun the in-house process of researching and developing an innovative diagnostic test to assist healthcare practitioners in determining Omega-3 deficiency. Current practice involves providing blood samples to a laboratory for analysis and reporting, a lengthy and time-consuming process. In order to conduct the in-house research the Company has built and outfitted a research laboratory that is dedicated to this project and the processing of clinical trial samples. Some of the costs associated with this project have been funded through an Industrial Research and Assistance Program (**"IRAP"**) grant and a Natural Sciences and Engineering Research Council of Canada **("NSERC")** grant. Research and development activities continue and progress thus far has been positive.

The Company continues its efforts to seek out business development opportunities. During 2014 and the first six months of 2015 Pivotal announced several Business development transactions.

In 2014 Pivotal executed an agreement with a recognized nationwide provider of U.S. sales data. This information is assisting the Company to track the effectiveness of its sales and marketing initiatives in its current limited Geographic area of New York, New Jersey and Pennsylvania. This data is also allowing the Company to identify new opportunities nationally where there is currently no sales representation. Sales of VASCAZEN® are reported in 37 states across the country. Physicians are writing prescriptions for VASCAZEN® in areas such as Texas, California, Louisiana, Ohio and Florida. The sales data is providing new targeting opportunities and allowing the Company to expand its sales strategy and demonstrates the Company's readiness for a true national sales partner.

On April 15, 2015 the Company announced having executed a memorandum of understanding with Korea Animal Medical Science Institute (**"KAMSI**") and its newly created affiliate for the exclusive sales and distribution of the Benefishial™ family of products.

Additional business development activities are under way with several companies that are currently assessing opportunities for representing Pivotal's products in Asia and the USA. The Company hopes to make additional positive business development announcements during 2015.

Pivotal continues to conduct research and development leading to the introduction of new products addressing unmet medical needs. On December 17, 2014 the Company announced that it had received approval from the French FDA to commence the clinical evaluation part of the VASCAZEN® POMEGA Phase IIa trial. The positive outcomes of the POMEGA trial would position VASCAZEN®'s formulation as a drug indication in Europe and potentially in the U.S marketplace.

The Company continues to invest in the expansion of its patent portfolio. As at the date of this report the Company has a patent portfolio that has grown to three (3) patents issued, one (1) patent allowed and seven (7) patents filed.

On June 29th, 2015 the Company announced that it proposed to raise up to $1,540,000 through a non-brokered private placement of up to 22,000,000 common shares of the Company at a price of $0.07 per common share. The completion of the financing is dependent upon receiving the prior written consent of the Company's existing Convertible Promissory Note ("Note") Holders. Under the terms of the Note such consent is not to be unreasonably withheld or delayed. As of the date of this report three out of seven Note Holders have given their consent. The net proceeds of the private placement will be used for general working capital. Efforts to close the financing continue.

GOALS

The Company continues to work towards the initial goal of further commercializing VASCAZEN® as a medical food and developing a pipeline of products utilizing VASCAZEN®'s unique and patented 6:1 EPA:DHA formulation. The Company is embarking on the next phase of its commercializing strategy as it seeks a national co-marketing partner.

VASCAZEN® is currently sold in the United States (**"U.S."**) as a prescription-only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating EPA and DHA to levels associated with reduced risk of cardiovascular complications.

OMAZEN® is being commercialized in the professional OTC market in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels. The Company recently received Health Canada approval to expand the indication of OMAZEN® to include products with claims for maintaining and supporting normal triglyceride levels and cardiovascular health. To increase the Company's presence in the OTC direct to retail market and direct to consumer market the Company created a new brand named Benefishial™.

The benefits of Omega-3 are well established and endorsed by the American Heart Association for use in the prevention of cardiovascular events in patients with coronary heart disease. Pivotal's medical food strategy is designed to position VASCAZEN® as the

pre-eminent Omega-3 product, and to differentiate it from the many over-the-counter supplements available and other prescription Omega-3 products. The differentiation will be driven by: (i) VASCAZEN®'s unique patented 6:1 EPA:DHA ratio; (ii) its anti-inflammatory properties; (iii) its high purity; (iv) the implementation of a far-reaching intellectual property strategy; (v) the physicians who will be targeted and (vi) the development of a rapid format POC test for monitoring Omega-3 blood levels. Cardiovascular disease has a high inflammatory component. Pivotal's high purity product, enriched with high EPA and a specific level of DHA, is capable of complementing the underlying metabolic processes of the cardiovascular system to restore the proper metabolic balance of inflammatory metabolites to reduce the inflammatory response at the cell membrane level, and thereby promote normal physiologic function and cardiac protection in patients with coronary heart disease.

STRATEGY

As a result of the information and experience the Company has acquired from selling VASCAZEN®, the Company has developed the following strategy for the further commercialization of its lead medical food product:

- Build and expand the sales force;
- Develop a specialized marketing program to create medical food awareness focusing on the correction of an Omega-3 deficiency;
- Implement a targeted reimbursement strategy for medical foods;
- Access a specialized medical food pharmacy to increase sales;
- Commercialize a point-of-care diagnostic to assist in the identification of Omega-3 deficient patients, monitor efficacy and compliance.

In order to achieve significant U.S. market revenues the Company estimates that a minimum of a 100 person sales force would be required. Given the current lack of financial resources the Company is actively seeking a co-marketing partner. The company has developed a strategy to increasing reimbursement levels for medical foods, which will have a positive impact at both the prescriber and patient levels. A specialized medical food pharmacy could facilitate sales to individuals with poor or no third party coverage and make the sales program seamless to all patients. The company is currently developing a rapid format point-of-care (**"POC"**) diagnostic test that can easily identify patients that are Omega-3 deficient at the physician's office, clinics and pharmacies.

The Company believes that these are the key components for the successful selling, marketing and positioning of a medical food.

Intellectual Property

The Omega-3 patent field is crowded, with at least one dominant player focused on its own specific EPA:DHA ratio (that differs from the Company's ratio). Based on an extensive patent review, however, Pivotal believes that its unique formulation allows for freedom-to-operate. On February 22, 2012, Pivotal filed five international patent applications under the Patent Cooperation Treaty (**"PCT"**), directed towards its novel

lead product VASCAZEN® and combinations thereof with certain cardiovascular treatment agents. A PCT application establishes a filing date in each of the 148 contracted PCT countries that Pivotal designates, including the United States of America, thereby securing patent pending status for VASCAZEN®. Pivotal continues to make efforts towards the expansion of its intellectual property portfolio.

On May 7, 2014, the Company announced the issuance of U.S. Patent 8,715,648 for its unique 6:1 EPA:DHA formulation. The issuance of this patent represents an important step in further protecting and advancing the commercial potential of VASCAZEN®'s formulation. This patent covers Pivotal's unique formulation in conjunction with anti-obesity agents for the reduction of body weight in patients with cardiovascular disease (**"CVD"**) and diabetics. This patent has terms that expire no earlier than 2031.

On October 7, 2014, the Company received notification of patent allowance for U.S. application serial number 13/584,480 related to a combination product of VASCAZEN® and statin therapy. On February 10, 2015, the Company announced the issuance of U.S. Patent Number 8,951,514 titled "STATIN and Omega-3 Fatty Acids for Reduction of Apolipoprotein-B levels".

On October 8, 2014, the Company received notification of patent allowance for U.S. patent application serial number 13/584,403 related to a combination product of VASCAZEN® and cholesterol absorption inhibitor. On February 10, 2015, the Company announced the issuance of U.S. Patent Number 8,952,000 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events".

On April 1, 2015, the Company received notification of patent allowance for U.S. application serial number 13/584,428 related to a kit for the dietary management of cardiovascular patients that includes VASCAZEN® and an Omega-3 fatty acid diagnostic assay.

These patent applications, patents allowed and issued patents are part of an expanding patent portfolio for Pivotal protecting its unique formulation with three (3) patent applications now issued and one (1) allowed and seven (7) additional applications pending in the United States Patent and Trademark Office **("USPTO**"). Pivotal is also pursuing patent applications related to VASCAZEN®'s formulation in multiple jurisdictions outside the United States.

Development of a Rapid Format POC Test

This diagnostic test will assist physicians and healthcare professionals in the identification of the desired population, those individuals deficient in EPA and DHA, and permits point-of-care (POC) monitoring of patient Omega-3 levels, compliance and effectiveness of VASCAZEN®.

Update on VASCAZEN®

Revenues for the three and six months ended June 30, 2015 are $114,663 and $268,176 as compared to $73,791 and $126,323 for the three and six months ended June 30, 2014. While sales to date of the U.S. product, VASCAZEN®, have been limited, acceptance by

healthcare professionals is growing and the increased awareness of VASCAZEN® is generating sales in several U.S. states that are not currently serviced by Pivotal sales representatives. Sales data indicates that our sales representatives are achieving competitive levels of prescriptions written and filled but the limited number of sales and marketing resources is affecting overall financial results. Realizing that current efforts to expand the in-house sales team have been hampered by limited financial resources, the Company has recently increased its efforts in the identification and contacting of sales groups or companies with a sales network that calls on the same targeted health care practitioners. The Company has also recently switched to a commission-based sales force compensation model. The increase in sales is due in part to channel restocking and as evidenced by an increase in returns associated with expired product.

Update on OMAZEN®

OMAZEN® is a greater than 90% pure, pharmaceutical grade Omega-3 for the maintenance of good health. OMAZEN® has a proprietary formulation delivering optimal levels of Omega-3 that promotes an increase in blood flow, reduced inflammation and positive effects on blood lipids contributing to the maintenance of good health. The Company recently received Health Canada approval to expand the indication of OMAZEN® to include products with claims for maintaining and supporting normal triglyceride levels and cardiovascular health.

Introduction of Benefishial™

In an effort to differentiate Pivotal's unique patented 6:1 EPA:DHA formulation with OTC products and to address new market segments Pivotal created the Benefishial™ line of products. The product line was specifically designed to be sold in the OTC direct to retail or direct to consumer markets. Benefishial™ is greater than 90% pure and contains the highest content of Omega-3 fatty acids than any other OTC product on the market. It is specifically formulated to give the highest anti-inflammatory properties and the best therapeutic effect for a healthy body and mind. It corrects the imbalance that the typical North American diet high in Omega-6 (pro-inflammatory) creates. Benefishial™'s unique formulation is clinically shown to increase blood levels of Omega-3. Benefishial™ is third party tested and goes through a five-step purification process to remove all toxins and fillers. It is monitored for freshness throughout the manufacturing process, tested by third parties and is packaged using blister packaging to maintain this freshness. Benefishial™ contains the optimal purity, ratio and dose of any Omega-3. Benefishial™ is a simple solution to a number of health risk factors.

The Benefishial™ product line currently consists of the following six products: (i) Benefishial™ for overall health, (ii) Benefishial™ for cardiovascular health, (iii) Benefishial™ for prenatal health, (iv) Benefishial™ for toddler's health, (v) Benefishial™ for child's health and (vi) Benefishial™ for pet's health (veterinary application).

Drug Candidate – PVT-100

Pivotal introduced PVT-100 as its first drug candidate. PVT-100's indication is for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. The development of PVT-100 is connected to the successful execution of the Company's POMEGA Phase IIa clinical trial. The trial is scheduled to commence in the first half of 2015.

PUBLICATOIN OF VASCAZEN®-REVEAL CLINICAL TRIAL

On May 7, 2013, the Company announced that it had presented positive results from the completion of the VASCAZEN®-REVEAL clinical trial. The results and conclusions derived from this clinical trial were significant. The results were presented on May 3, 2013, at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology ("**ATVB**") 2013 Scientific Sessions.

The purpose of the VASCAZEN®-REVEAL trial was to demonstrate that CVD patients are nutritionally deficient in Omega-3 fatty acids, and through treatment with VASCAZEN® such deficiency can be corrected, resulting in the improvement of patient lipid profiles and ultimately reducing CVD risk factors. The trial was a double-blind, placebo-controlled study comprised of 110 subjects randomized and stratified by baseline triglyceride levels. The trial analyzed both the placebo (n=54) and VASCAZEN® treated (n=56) groups at baseline and after eight weeks of treatment. The primary endpoints were the change in the Omega-Score and Omega-Index, with secondary endpoints including the change in serum triglyceride, lipoprotein cholesterol (VLDL, LDL, HDL, ApoB, and subfractions), and hsCRP. The Omega-Score and Omega-Index are proprietary diagnostic tests that measure circulating blood levels of Omega-3 in individuals. The Omega-Score and Omega-Index are independent measures of risk factors for CVD. The levels correlate with the risk of CVD events; patients with low levels of Omega-3 have a higher incidence of CVD events than patients with high levels of Omega-3.

VASCAZEN® was demonstrated to be highly effective in correcting an Omega-3 deficiency. In eight weeks of treatment a statistically significant ($p<0.0001$) increase of 121% in the Omega-Score and 112% ($p<0.0001$) in Omega-Index (the blood levels of EPA, DHA and Docosapentaenoic acid, (**"DPA"**) was observed in VASCAZEN® treated subjects. The VASCAZEN®-REVEAL trial confirms Pivotal's Open Label Study results conducted in 2011 that identified >80% of CVD patients as Omega-3 deficient. The VASCAZEN® formulation had a profound effect on correcting an Omega-3 deficiency and positive effect on lipid profiles, mainly the reduction of triglycerides and raising HDL in as little as eight weeks of treatment.

The VASCAZEN®-REVEAL trial confirmed that Omega-3 deficiency is prevalent in individuals with CVD, and that such a deficiency can be corrected with VASCAZEN®, a 6:1 EPA:DHA Omega-3, resulting in a concomitant and significant placebo-corrected reduction in triglycerides and VLDL, and increase in HDL-C in patients with high triglycerides (200-500mg/dL), without adversely affecting LDL-C.

Of the 110 patients enrolled > 85% were Omega-3 deficient. The VASCAZEN®-REVEAL trial is the first to determine dietary levels of Omega-3 in plasma and in red blood cells using the Omega-Score and Omega-Index diagnostics. Improvement after treatment with VASCAZEN® and the concomitant beneficial effects on CVD risk factors in patients with high triglycerides (200-500mg/dL) was analyzed.

On September 10, 2014, Pivotal announced the publication of the results of a VASCAZEN®-REVEAL study in the peer-reviewed journal Molecular and Cellular

Biochemistry. It was a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN® in the correction of Omega-3 deficiency in patients with one or more risk factors associated with CVD and evaluated VASCAZEN®'s concomitant effects on these risk factors including triglycerides, VLDL cholesterol, LDL cholesterol, and HDL cholesterol.

The publication titled, "Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN®-REVEAL Trial," was authored by Nisar Shaikh, Jason Yantha, Sabah Shaikh, William Rowe, Maggie Laidlaw, Carla Cockerline, Abbas Ali, Bruce Holub and George Jackowski, MolCellBiochem (2014) 396:9-22 with open public access at http://link.springer.com/article/10.1007/s11010-014-2132-1/fulltext.html.

POMEGA Phase IIa CLINICAL TRIAL

On December 17, 2014, the Company announced that it had received approval from the French FDA to commence the clinical evaluation part of the VASCAZEN® POMEGA Phase IIa trial. The POMEGA trial is a double-blinded placebo controlled study to include over 100 patients scheduled to undergo vascular surgery for carotid endarterectomy at the University Hospital of Strasbourg, France. Patients will be randomized to receive either Pivotal's uniquely formulated VASCAZEN® product (PVT-100) or placebo for six consecutive weeks. The composite primary endpoint of the trial consists of histomorphological, biochemical and immunological status of the vascular plaque. The trial is being coordinated and monitored locally by Preventor TBC GMBH, a German drug safety corporation specialized in pre-clinical and clinical pharmacovigilance, that provides guidance to Pivotal in Europe. More than 4,000 patients are diagnosed with carotid plaque stenosis in France annually. The positive outcomes of the POMEGA trial would position VASCAZEN®'s formulation as a drug indication in Europe and potentially in the U.S. marketplace.

SELECTED FINANCIAL INFORMATION

TRENDS, RESULTS OF OPERATIONS AND ANNUAL RESULTS

Since October 1, 2010, the date of incorporation, the Company has concentrated its efforts in the organization, strategic development and financing of the Company and in securing its intellectual property position. On December 8, 2010, Pivotal Therapeutics Inc. (pre-amalgamation) entered into an amalgamation agreement with a reporting issuer, Media Script Marketing Inc., to amalgamate. The parties entered into a definitive agreement whereby the common shares of Pivotal (pre-amalgamation) and Media Script (consolidated shares) were each exchanged for the common shares of the amalgamated entity (the Company) on a one to one basis, after the common shares of Media Script had been consolidated on a two to one basis. This transaction was completed, resulting in the amalgamated entity continuing as the Company, effective April 7, 2011.

The period of three and six months ended June 30, 2015 represents the beginning of Company's fifth year of operation as an amalgamated entity and represents a continuation of Pivotal Therapeutics Inc. (pre-amalgamation) for accounting purposes. Comparative figures are for the three and six months ended June 30, 2015 and the twelve months ended December 31, 2014.

The Company's operating expenses for the three and six months ended June 30, 2015 decreased to $760,381 and $1,603,162 respectively as compared to $2,062,528 and $3,539.190 for the three and six months ended June 30, 2014. Included in operating expenses is stock based compensation of $Nil and $Nil for the three and six months ended June 30, 2015 and $491,098 and $1,000,050 for the three and six months ended June 30, 2014. Stock based compensation expenses for 2014 are in recognition of deferred option awards to directors, officers, employees and consultants for 2012 and 2013. Also included in Net Loss are Accretion expense $364,550 and $705,427; Interest on long-term debt $156,145 and $308,895; Financing fees $Nil and $2,875 and a Loss on the change in fair value of conversion options of $142,056 and $128,110 account for a total of $662,751 and $1,145,307 of total net losses of $1,454,971 and $2,646,253 reported for the three and six months ended June 30, 2015.

Despite the delays in the completion of the Company's financing efforts, announced on June 29, 2015, many strategic business milestones were achieved by the Company during the twelve months ended December 31, 2014, and the first six months of 2015, including the following.

The Company has expanded its product pipeline. The product portfolio currently consists of three product lines; (i) VASCAZEN® is currently sold in the United States (**"U.S."**) as a prescription-only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease, (ii) OMAZEN® is being commercialized in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels and (iii) Benefishial™, which is targeting the direct to consumer and direct to retail marketplace and consists of six different products.

Pivotal has begun the in-house process of researching and developing an innovative diagnostic test to assist healthcare practitioners in determining Omega-3 deficiency. Current practice involves providing blood samples to a laboratory for analysis and reporting, a lengthy and time-consuming process. In order to conduct the in-house research the Company has built and outfitted a research laboratory that is dedicated to this project and the processing of clinical trial samples. Some of the costs associated with this project have been funded through an Industrial Research and Assistance Program (**"IRAP**") grant and a Natural Sciences and Engineering Research Council of Canada (**"NSERC"**) grant.

The Company continues its efforts to seek out business development opportunities. During 2014 and the first six months of 2015 Pivotal announced several Business development transactions.

Pivotal executed an agreement with a recognized nationwide provider of U.S. sales data. This information is assisting the Company to track the effectiveness of its sales and marketing initiatives in its current limited geographic area of New York, New Jersey and Pennsylvania. This data is also allowing the Company to identify new opportunities nationally where there is currently no sales representation. Sales of VASCAZEN® are reported in 37 states across the country. Physicians are writing prescriptions for VASCAZEN® in areas such as Texas, California, Louisiana, Ohio and Florida. The sales data is providing new targeting opportunities and allowing the Company to expand its sales strategy and demonstrates the Company's readiness for a true national sales partner.

On April 15, 2015, the Company announced having executed a memorandum of understanding with Korea Animal Medical Science Institute (**"KAMSI"**) and its newly created affiliate for the exclusive sales and distribution of the Benefishial™ family of products.

Additional business development activities are under way with several companies that are currently assessing opportunities for representing Pivotal's products in Asia and the USA. The Company hopes to make additional positive business development announcements during 2015.

Pivotal continues to conduct research and development leading to the introduction of new products addressing unmet medical needs. On December 17, 2014, the Company announced that it had received approval from the French FDA to commence the clinical evaluation part of the POMEGA Phase IIa trial. The positive outcomes of the POMEGA trial would position VASCAZEN®'s formulation (PVT-100) as a drug indication in Europe and potentially in the U.S. marketplace.

The Company continues to invest in the expansion of its patent portfolio. As at the date of this report the Company has a patent portfolio that has grown to three (3) patents issued, one (1) patent allowed and seven (7) patents filed.

Sales

Product sales for the three and six months ended June 30, 2015 are $114,663 and $268,176 as compared to $73,791 and $126,323 for the three and six months ended June 30, 2014. The increase in sales is due in part to channel restocking and as evidenced by an increase in returns associated with expired product. Sales and marketing expenses decreased to $130,471 and $392,285 for the three and six months ended June 30, 2015 as compared to $559,304 and $815,752 for the three and six months ended June 30, 2014. Sales and marketing expenses decreased by 77% for the three months and 52% for the six months ended June 30, 2015 as compared to the three and six months ended June 30, 2014. While sales to date of the U.S. product, VASCAZEN®, have been limited, acceptance by healthcare professionals continues to grow and the increased awareness of VASCAZEN® is generating sales in several U.S. states that are not currently serviced by Pivotal sales representatives. Sales data indicates that our sales representatives are achieving competitive levels of prescriptions written and filled, but the limited number of sales and marketing resources is negatively affecting overall financial results. Realizing that current efforts to expand the in-house sales team have been hampered by limited financial resources, the Company has recently increased its efforts in the identification and contacting of sales groups or companies with a sales network that calls on the same targeted health care practitioners.

In an effort to address new market segments Pivotal developed a new product brand, Benefishial™, that is being directed towards the over the counter market. Currently the Company is seeking to develop commercial relationships for the U.S., International and Canadian market.

Expenses

The Company anticipates that expenses will continue to increase commensurate with an increase in sales and marketing activity, research and development, business development and expansion of its product portfolio.

During the three and six months ended June 30, 2015, the Company had sales and marketing expenses of $130,471 and $392,285 as compared to $559,304 and $815,752 for the three and six months ended June 30, 2014, an decrease of $428,833 and $423,467 respectively. Despite the fact that sales and marketing efforts continue to be impacted from the lack of financial resources, that first occurred in 2013, the Company has been able to sell product in 37 states across the U.S. even though our direct sales force efforts, to date, have concentrated only in three states. This positive experience demonstrates the company's readiness for a true national co-marketing partner.

During the three and six months ended June 30, 2015, the Company had stock-based compensation of $Nil and $Nil as compared to $491,098 and $1,000,050 for the three and six months ended June 30, 2014. Stock-based compensation represents the fair value of the options granted during the three and six months ended June 30, 2014 and was determined using the Black-Scholes option pricing model. The June 30, 2014 amount reflects the value associated with the issuance of options to acquire 9,251,000 common shares of the Company. The Company had deferred the issuance of 8,251,000 options until it concluded its equity financing. On March 14, 2014, the Company granted previously reserved stock options to certain of its directors, officers, employees and

consultants in recognition of awards deferred from 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of the grant. The increase also includes the value attributed to options issued on April 7, 2014. On April 7, 2014, the Company granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of awards deferred from 2013. Options to acquire a total of 4,176,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. Included in the total are 250,000 options granted to Crossover Healthcare Fund, LLC in recognition of services provided. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of the grant. In addition, on September 15, 2014, the Company announced the granting of 1,000,000 stock options to an officer and consultant. The stock options were granted effective September 12, 2014, are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.

During the three and six months ended June 30, 2015, the Company had salaries and benefits expenses of $213,356 and $369,002 as compared to $224,360 and $448,035 for the three and six months ended June 30, 2014. The three and six month decrease of $11,004 and $144,642 reflects a decrease in overall executive compensation for the period.

During the three and six months ended June 30, 2015, the Company had research and development costs of $113,298 and $250,881 as compared to $207,727 and $373,500 for the three and six months ended June 30, 2014. The three and six month decrease of $94,429 and $122,619 in research and development costs is directly attributed to establishing normalized expenditure levels in comparison to the higher costs associated with the Company having established its own in-house research laboratory for the first time in 2014. One of the main purposes for the in-house laboratory is to enhance the Company’s research capabilities in the development of new products. Research and development cost are planned to continue to increase during 2015 in conjunction with an expansion of in-house research staff and activities leading to the development of a rapid format point-of-care Omega-3 diagnostic. The Company is developing a rapid format diagnostic, which can be used in the physician offices, to provide an analysis of a patient’s Omega-3 deficiency levels.

During the three and six months ended June 30, 2015, the Company had consulting expenses of $110,300 and $225,800 as compared to $164,708 and $336,083 for the three and six months ended June 30, 2014. The decrease of $54,408 for the three months and $110,283 for the six months ended June 30, 2015 relates to a decrease in the number of consultants’ activity associated with business development and product sales.

During the three and six months ended June 30, 2015, the Company had office and general administration expenses of $81,214 and $153,806 as compared to $215,225 and $292,784 for the three and six months ended June 30, 2014. Included in the three and six

month decrease of $134,011 and $138,978 are foreign exchange losses of $25,303 and $43,225 respectively.

During the twelve months ended December 31, 2013, the Company was required to provide an inventory impairment provision of $271,068. An additional amount of $304,475 has been provided for the twelve months ended December 31, 2014. This provision relates to the possibility that a portion of existing VASCAZEN® and OMAZEN® inventories will not be distributed or sold prior to the expiration date of the product based on forecasted sales levels. Pivotal had produced sufficient inventory to meet with projected demand resulting from anticipated increase in sales and marketing efforts. The delays in financing for the Company had a serious negative effect on sales and marketing activities for 2013 and 2014 resulting in downward revisions to forecasted sales. No additional provision was deemed necessary for the three and six months ended June 30, 2015.

During the three and six months ended June 30, 2015, the Company had professional fees of $38,563 and $73,217 as compared to $137,774 and $162,839 for the three and six months ended June 30, 2014, an decrease of $99,211 for the three months and $89,622 for the six months ended June 30, 2015. The three and six month decrease reflects timing delays in legal billings and a reduction in activity associated with corporate legal matters.

During the three and six months ended June 30, 2015, the Company had rent and utilities expenses of $22,770 and $45,014 as compared to $20,659 and $38,613 for the three and six months ended June 30, 2014, an increase of $2,111 for the three months and $6,401 for the six months ended June 30, 2015. The increase relates to an expansion of space requirements in connection with the establishment of an in-house research facility.

During the three and six months ended June 30, 2015, the Company had depreciation expenses of $24,550 and $49,090 as compared to $17,803 and $32,203 for the three and six months ended June 30, 2014. The three month increase of $6,747 and the six month increase of $16,887 in depreciation is related to increased purchases of research and development equipment made in connection with the Company expanding its in-house research facility for the purposes of pursuing a rapid-format diagnostic test to assist healthcare practitioners in determining Omega-3 deficiency.

During the three and six months ended June 30, 2015, the Company had registration fees of $14,882 and $22,647 as compared to $14,559 and $21,605 for the three and six months ended June 30, 2014. An increase of $323 for the three months and $1,042 for the six months ended June 30, 2015. These costs are associated with the Company being listed on two exchanges, the Canadian Securities Exchange ("**CSE**") (formerly "**CNSX**") and the OTC Markets QX ("**OTCQX**").

During the three and six months ended June 30, 2015, the Company had amortization of intangible assets expenses of $10,977 and $21,420 as compared to $9,311 and $17,726 for the three and six months ended June 30, 2014. This expense pertains to the amortization of intellectual property. Intellectual property had a carrying value of $786,242 as at December 31, 2014. Intellectual property expenditures of $21,324 and $70,525 during the three and six months ended June 30, 2015 resulted in an increase to

intangible assets cost. The amortization of the increase in value explains the increase in amortization expense for the three and six months ended June 30, 2015.

During the three and six months ended June 30, 2015, the Company had recorded accretion expense of $364,550 and $705,427 as compared to $Nil for the three months and $111,343 for the six months ended June 30, 2014. Accretion expense relates to the Company's Convertible Promissory Notes, as described in Note 7 to the consolidated financial statements for the period ended December 31, 2014. This expense reflects the difference, which is recognized as an expense over the life of the Notes, between the face value of the promissory notes and the fair value at which they are reported in the Company's statement of financial position.

During the three and six months ended June 30, 2015, the Company had interest on long-term debt of $156,145 and $308,895 as compared to $154,170 for the three months and $201,692 for the six months ended June 30, 2014. The increase of $1,975 for the three months and $107,203 for the six months ended June 30, 2015 relates to paid and or accrued interest on the Notes for the full period.

During the three and six months ended June 30, 2015, the Company recorded a loss on the change in fair value of conversion option of $142,056 and $128,110 as compared to $Nil for the three months and $Nil for the six months ended June 30, 2014. The $142,056 for the three months and $128,110 for the six months ended June 30, 2015 relates to the convertible note financing. The Company recognized a conversion option derivative liability measured at fair value with subsequent changes in fair value accounted for through the consolidated statements of loss and comprehensive loss, see Note 8 of the audited financial statements for additional details.

Trends

Based on completion of its initial private placements, amalgamation, and warrant exercise, the Company was able to fund its initial growth plan and begin to commercialize its lead product, VASCAZEN®.

Effective February 2013, the Company has directly employed its sales force. This action has resulted in a more effective control of the sales force, reduced costs of operation and increased sales. Bringing the sales team in-house has provided greater understanding of the U.S. market. The experiences gained are expected to better enable management to develop and execute a more effective sales and marketing strategy for the future. The Company anticipates that over time positive results will be achieved.

Sales, marketing, product distribution, clinical trials and reimbursement activities undertaken and managed during the twelve months ended December 31, 2013 and December 31, 2014 and the six months ended June 30, 2015, were restricted as the Company made every effort to control costs, preserve financial resources and seek out capital.

On October 2, 2013, the Company announced that the equity portion of its private placement had raised gross proceeds of $2,741,809, and issued 12,462,768 units at a price of $0.22 per unit. Each unit consisted of one common share and one-half purchase warrant. Prior to closing, the terms of the purchase warrants were revised from an expiry of 24 months to 60 months and the warrants' exercise price was revised from $0.50 per common share to $0.30 per common share. The purchase warrants may be called by the Company at any time after six months following the closing, provided the common shares of the Company have traded at a price of at least $0.45 for 20 trading days within a 30 day consecutive trading period.

On March 4, 2014, the Company completed its debt financing that had been announced in October 2013, resulting in the issuance of 7,744 Convertible Promissory units for gross proceeds of $7,743,580. Each unit consists of $1,000 Convertible Promissory Notes ("**Notes**") and 1,200 common share purchase warrants for a total issuance of 9,292,296 warrants. The warrants may be exercised at any time for a period of 60 months following the date of issuance at an exercise price of $0.30 per common share. The Company also incurred financing costs associated with the transaction of $480,544 and issued an aggregate of 1,641,586 Agent warrants. The agent warrants may be exercised at a price of $0.30 for a period of 60 months and have an expiry date of March 4, 2019. The maturity of the Notes is two years from the date of issuance. Subsequent to the year-end, the conversion price of the Notes was amended from $0.25 to $0.20 for each common share of the Company, the maximum amount of the offering was increased from $5,000,000 and the warrant exercise price was reduced from $0.50 per common share to $0.30. The Notes accrue interest at 8% per annum due and payable quarterly with the first payment due three months from the date of issuance, (July 1, 2014). The Company may, at its discretion, pay the interest in either cash or common shares of the Company, valued at the greater of $0.20 per share and such price as may be allowed under the CSE's policy (CNSX policy).

As at July 1, 2014, the Company made the first interest payment of $156,145 in cash. As at October 1, 2014, the Company made the second interest payment of $156,145 by issuing 780,722 common shares of the Corporation (**"Common Shares"**) representing payment of interest for the period of June 5, 2014 to September 4, 2014 on its outstanding Convertible Notes. As at December 17, 2014, the Company made the third interest payment of $154,447 by issuing 772,236 common shares of the Corporation representing payment of interest for the period of September 5, 2014 to December 4, 2014 on its outstanding Convertible Notes. As at March 4, 2015, the Company made the fourth interest payment of $152,750 by issuing 763,752 common shares of the Corporation representing payment of interest for the period of December 5, 2014 to March 4, 2015 on its outstanding Convertible Notes.

On June 29, 2015, the Company announced that is proposed to raise up to $1,540,000 through a non-brokered private placement of up to 22,000,000 common share of the Company at a price of $0.07 per common share. Finders' fees will be paid in connection with the private placement. The completion of the financing is dependent upon receiving the prior written consent of the Company's existing Convertible Promissory Note Holders. Under the terms of the Convertible Promissory Note such consent is not to be unreasonably withheld or delayed. As of the date of this report three out of seven Note

Holders have given their consent. The net proceeds of the private placement will be used for general working capital. Efforts to close the financing continue.

The following tables provide selected financial information that should be read in conjunction with the audited consolidated financial statements and the unaudited condensed interim consolidated financial statements of the Company.

SUMMARY OF SELECTED QUARTERLY RESULTS

Income Statement Items	**Three Months ended June 30, 2015 (unaudited)**	**Three Months ended March 31, 2015 (unaudited)**	**Three Months ended December 31, 2014 (unaudited)**	**Three Months ended September 30, 2014 (unaudited)**	**Three Months ended June 30, 2014 (unaudited)**
Total Net Revenues	$(9,859)	$153,513	$107,728	$72,544	$73,791
Net (Loss)	$(1,454,971)	$(1,192,282)	$(106,125)	$(1,632,052)	$(2,172,778)
Weighted Average Number of Shares Outstanding	95,013,710	93,706,848	92,151,238	91,916,277	91,916,277
Loss per Common Share	$(0.02)	$(0.01)	$(0.00)	$(0.02)	$(0.02)

Statements of Financial Position as at	**June 30, 2015 (unaudited)**	**December 31, 2014 (audited)**
Assets		
Current Assets	$338,582	$1,089,584
Equipment	$389,643	$424,929
Intangible Assets	$721,534	$672,429
Total Assets	$1,449,759	$2,186,942
Liabilities		
Current Liabilities	$8,237,243	$528,862
Long Term Liabilities	$-	$6,108,206
Total Liabilities	$8,237,243	$6,637,068
Shareholders' Equity		
Share Capital	$8,581,833	$8,272,938
Other Paid-in Capital	$2,495,812	$2,495,812
Warrants	$732,645	$732,645
Deficit	$(18,597,774)	$(15,951,521)
Total Liabilities and Shareholders' Equity	$1,449,759	$2,186,942

LIQUIDITY AND CAPITAL RESOURCES

The consolidated financial statements are prepared in accordance with International Financial Reporting Standards (**"IFRS"**) as issued by the international Accounting Standards Board (**"IASB"**) and on the assumption that the Company will be able to realize the carrying value of its assets and discharge its liabilities in the normal course of operations as a going concern. The Company's ability to discharge its liabilities and realize the carrying value of its assets in the normal course of operations is dependent upon, among other things, being able to raise the required capital amount of debt and/or equity financing for profitable operations to be achieved.

The Company's first private placement occurred through the issuance of a unit ("**Unit**") consisting of one common share and one-half of one common share purchase warrant, with a subscription price of $0.10 per Unit. As at February 2, 2011, the Company was successful in completing the first private placement resulting in gross proceeds of $2,378,844.

On July 14, 2011, after having met the conditions of an Accelerated Event, the Company issued a call on the share purchase warrants. Following an extension of the exercise period, Warrant holders of record had until 5:00 pm on September 16, 2011 to exercise their warrants, with each full warrant, at a price of $0.25 per common share, entitling the holder to purchase one common share in the capital of the Company. The cumulated exercise of 10,466,392 common stock purchase warrants resulted in net proceeds of $2,616,598.

On June 25, 2012, the Company announced having entered into a subscription agreement for a $5,000,000 non-brokered private placement with a U.S, Institutional Fund, Crossover Healthcare Fund, LLC. Pursuant to the subscription agreement, the Company had agreed to issue 22,727,273 units at a price of $0.22 each. Each unit consisted of one common share and one-half purchase warrant. Each full purchase warrant may be exercised to purchase one common share of the Company upon payment of the exercise price of $0.50 per common share. Units were to be issued in tranches as funds were received. The purchase warrants were to expire 24 months following the closing of each tranche and may be called by the Company at any time after six months following the closing, provided the common shares of the Company have traded at a price of at least $0.75 per share for 20 trading days within a 30 day consecutive trading period.

On October 2, 2013, the Company announced that equity portion of the private placement had raised gross proceeds of $2,741,809 representing 12,462,768 units at a price of $0.22 per unit. Each unit consist of one common share and one-half purchase warrant. The terms of the purchase warrants were revised from an expiry of 24 months to 60 months. The warrants' exercise price was reduced from $0.50 per common share to $0.30 per common share. The purchase warrants may be called by the Company at any time after six months following the closing, provided the commons shares of the Company have traded at a price of at least $0.45 for 20 trading days within a 30 day consecutive trading period.

On March 4, 2014, the Company completed its debt financing that had been announced in October 2013, resulting in the issuance of 7,744 Convertible Promissory units for gross proceeds of $7,743,580. Each unit consists of $1,000 Convertible Promissory Notes (**"Notes"**) and 1,200 common share purchase warrants for a total issuance of 9,292,296 warrants. The maturity of the Notes is two years from the date of issuance. Subsequent to the year-end, the conversion price of the Notes was amended from $0.25 to $0.20 for each common share of the Company, the maximum amount of the offering was increased from $5,000,000 and the warrant exercise price was reduced from $0.50 per common share to $0.30. The Notes accrue interest at 8% per annum due and payable quarterly with the first payment due three months from the date of issuance, (July 1, 2014). The Company may, at its discretion, pay the interest in either cash or common shares of the Company, valued at the greater of $0.20 per share and such price as may be allowed under the CSE's policy (CNSX policy). The warrants may be exercised at any time for a period of 60 months following the date of issuance at an exercise price of $0.30 per common share. The Company also incurred financing costs associated with the transaction of $480,533 and issued an aggregate of 1,641,586 agent warrants. The agent warrants may be exercised at a price of $0.30 for a period of 60 months and have an expiry date of March 4, 2019.

On June 29, 2015, the Company announced that it proposed to raise up to $1,540,000 through a non-brokered private placement of up to 22,000,000 common share of the Company at a price of $0.07 per common share. Finders' fees will be paid in connection with the private placement. The completion of the financing is dependent upon receiving the prior written consent of the Company's existing Convertible Promissory Note Holders. Under the terms of the Convertible Promissory Note such consent is not to be unreasonably withheld or delayed. As of the date of this report three out of seven Note Holders have given their consent. The net proceeds of the private placement will be used for general working capital. Efforts to close the financing continue.

There are currently no defaults or arrears by the Company on:

i) Dividend payments, lease payments, interest or principal payment on debt;
ii) Debt covenants; or
iii) Redemption or retraction or sinking fund payments.

As of the date of this MD&A, the Company did not have any commitments for capital expenditures.

At June 30, 2015, the Company had cash totaling $11,319 compared to $466,904 at December 31, 2014. The net decrease in cash relates to the Company's funding of daily operations and the lack of cash inflows resulting from significant revenues.

Working capital (defined as current assets minus current liabilities) has decreased to $(7,898,661) for the six months ended June 30, 2015 as compared to $560,722 for the year ended December 31, 2014, mainly as a result of the convertible promissory notes having a maturity date of less than one year. In addition a decrease in financing activities, a reduction in cash used for operating activities, and an increase in the acquisition of equipment and intangible asset additions contributed to the decrease. In

order for the Company to sustain operations it will require additional capital. The Company expects to satisfy operating cash requirements over the next twelve months from cash on hand, collection of anticipated revenues resulting from commercialization activities, development or marketing license agreements, through managing operating expenses and additional equity or debt financings. There are no assurances that Pivotal will be able to obtain any new capital on desirable terms or in amounts sufficient to meet its operating needs. The availability of financing for the Company will be affected by, amongst other things, the success of its commercialization efforts, the results of its clinical studies, the market acceptance of its products, the general state of the capital markets, its strategic alliance agreements and other commercial factors. In the event that Pivotal is unable to obtain additional capital over the next twelve months, there may be substantial doubt about the Company's ability to continue as a going concern and realization of assets and payment of liabilities as they become due.

CAPITAL EXPENDITURES

Total capital expenditures additions for the six months ended June 30, 2015 were $13,804, compared to the December 31, 2014 amount of $418,706. Capital expenditures for the six months ended June 30, 2015 all relate to the purchase of research equipment and the expansion of the Company's research facilities. Total capital expenditures for 2015 are anticipated to increase insignificantly as the majority of planned purchases took place during the twelve months ended December 31, 2014. The Company continues to fund capital expenditures from working capital.

CONTRACTUAL OBLIGATIONS

The Company had entered into a lease for office premises, which was scheduled to expire on January 31, 2013, with an option to renew the term of the lease for a further three years. The Company exercised the option for a further three years expiring January 2016. The minimum annual rental payments to the end of the lease term are as follows:

2015: $39,000
2016: $3,300

On December 1, 2013, the Company entered into a new lease for additional office space, which expires November 30, 2016. The minimum annual rental payments to the end of the lease term are as follows:

2015: $25,400
2016: $23,283

DISCLOSURE CONTROL AND PROCEDURES

Under the supervision and with the participation of Pivotal's management, including the Chief Executive Officer, Chief Operating Officer and President and Chief Financial Officer, Pivotal has evaluated the effectiveness of its disclosure controls and procedures as at June 30, 2015. Disclosure controls and procedures are designed to ensure that the information required to be disclosed by the Company in the reports it files or submits under securities legislation is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and reported to management, including the Company's Chief Executive Officer, Chief Operating Officer and President and Chief Financial Officer, as appropriate, to allow required disclosures to be made on a timely basis. Based on the evaluation, management has concluded that these disclosure controls and procedures are effective.

INTERNAL CONTROL OVER FINANCIAL REPORTING

The management of the Company is responsible for establishing and maintaining effective internal control over financial reporting.

Internal control over financial reporting include those policies and procedures that establish the following: maintenance of records in reasonable detail, that accurately and fairly reflect the transactions and dispositions of assets; reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with applicable generally accepted accounting principles; receipts and expenditures are only being made in accordance with authorizations of management and the Board of Directors; and reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets.

Management has designed internal controls over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Canadian generally accepted accounting principles.

Management has concluded that internal control over financial reporting is effective. The design and operation of internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with applicable generally accepted accounting principles.

OFF BALANCE SHEET ARRANGEMENTS

As at August 28, 2015, the Company did not have any off-balance sheet arrangements.

PROPOSED TRANSACTIONS

On June 29, 2015, the Company announced that is proposed to raise up to $1,540,000 through a non-brokered private placement of up to 22,000,000 common share of the Company at a price of $0.07 per common share. Finders' fees will be paid in connection

with the private placement. The completion of the financing is dependent upon receiving the prior written consent of the Company's existing Convertible Promissory Note Holders. Under the terms of the Convertible Promissory Note such consent is not to be unreasonably withheld or delayed. As of the date of this report three out of seven Note Holders have given their consent. The net proceeds of the private placement will be used for general working capital. Efforts to close the financing continue.

TRANSACTIONS WITH RELATED PARTIES

The Company paid or accrued a total of $180,000 in consulting fees to an officer and director of the Company for the six months ending June 30, 2015, compared to $180,000 for the six months period ended June 30, 2014. The Company paid or accrued a total of $270,000 in management compensation for the six months ending June 30, 2015, compared to $334,630 for the six months period ended June 30, 2014.

As at June 30, 2015, $228,007 was owing to officers and directors of the Company for unpaid director's meeting fees, compensation and expenses as compared to $11,798 as at December 31, 2014.

CONTINGENCIES

As at the date of this report, the Company did not have any contingencies outstanding.

OUTSTANDING SHARE DATA

As at:	June 30, 2015	December 31, 2014
Authorized:		
Unlimited number of common shares without par value		
Issued and Outstanding:		
Common shares (1)	95,013,710	93,469,236
Common share value	$8,581,833	$8,272,938
Common share purchase warrants to be issued	17,165,266	17,165,266
Common share purchase warrants to be issued value	$5,149,579	$5,149,579
Stock options exercisable at $0.10, expiry Jan 11, 2016	300,000	300,000
Stock options exercisable at $0.10, expiry Feb 7, 2016	200,000	200,000
Stock options exercisable at $0.10, expiry Mar 10, 2016	799,000	899,000
Stock options exercisable at $0.45, expiry May 24, 2016	1,500,000	1,500,000
Stock options exercisable at $0.30, expiry Aug 18, 2016	100,000	100,000
Stock options exercisable at $0.30, expiry Aug 26, 2016	300,000	550,000
Stock options exercisable at $0.25, expiry Nov 22, 2016	200,000	200,000
Stock options exercisable at $0.29, expiry Mar 29, 2017	200,000	200,000
Stock options exercisable at $0.20, expiry Mar 14, 2019	3,550,000	3,800,000
Stock options exercisable at $0.20, expiry April 7, 2019	3,326,000	3,576,000
Stock options exercisable at $0.20, expiry Sept 12, 2019	500,000	1,000,000
Total stock options issued and outstanding	10,975,000	12,325,000
Total stock options exercised	1,000	1,000
Total stock options available for issuance	3,276,057	1,694,385
Total stock option plan (15% of common share issued and outstanding)	14,252,057	14,020,385

COMMON SHARES

On October 2, 2013, the Company announced that the equity portion of the private placement had raised gross proceeds of $2,741,809 representing 12,462,768 units at a price of $0.22 per unit. Each unit consist of one common share and one-half purchase warrant.

WARRANTS

For the six months ended June 30, 2015 there were 17,165,266 warrants issued and outstanding.

Pursuant to the private placement, the closing of the equity portion, which was announced on October 2, 2013, the Company issued 6,231,384 common share purchase warrants, each of which purchase warrant may be exercised to purchase one common share of the Company upon payment of the exercise price of $0.30 per common share. The purchase warrants expire 60 months following the closing and may be called by the Company at any time after six months following the closing, provided the common shares of the Company have traded at a price of at least $0.45 per share for 20 trading days within a 30 day consecutive trading period. To date no warrants issued in connection with this financing have been exercised.

On March 4, 2014, the Company completed its debt financing that had been announced in October 2013, resulting in the issuance of 7,744 Convertible Promissory units for gross proceeds of $7,743,580. Each unit consisted of $1,000 Convertible Promissory Notes ("**Notes**") and 1,200 common share purchase warrants, for a total issuance of 9,292,296 warrants. The maturity of the Notes is two years from the date of issuance. The Notes may be converted at a price of $0.20 for each common share of the Company. The warrant exercise price is $0.30 per common share. The Notes accrue interest at 8% per annum due and payable quarterly with the first payment due three months from the date of issuance, (July 1, 2014). The Company may, at its discretion, pay the interest in either cash or common shares of the Company, valued at the greater of $0.20 per share and such price as may be allowed under the CSE's policy (CNSX policy). The warrants may be exercised at any time for a period of 60 months following the date of issuance at an exercise price of $0.30 per common share. The Company also incurred financing costs associated with the transaction of $480,544 and issued an aggregate of 1,641,586 agent warrants. The agent warrants may be exercised at a price of $0.30 for a period of 60 months and have an expiry date of March 4, 2019.

STOCK OPTIONS

No stock options were granted during the year ended December 31, 2013. No options were exercised during the year ended December 31, 2014. On February 1, 2014, 100,000 stock options granted August 26, 2011 to a past employee were not exercised within the required option period following the employee departure and expired. On March 14, 2014, the Company granted previously reserved stock options to certain of its directors, officers, employees and consultants that were deferred from 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of the grant. On April 7, 2014, the Company granted previously reserved stock options to certain of its directors, officers, employees and consultants that were deferred from 2013. Options to acquire a total of 4,176,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of the grant. In addition, on September 15, 2014 the Company announced the granting of 1,000,000 stock options to an officer and consultant. The stock options were granted effective September 12, 2014 are exercisable at an exercise price of $0.20 and will expire five years following the date of grant. On July 17, 2014, 250,000 stock options, granted March 14, 2014 to a past director were not exercised within the required option period following the director's departure and expired. On July 17, 2014, 500,000 stock options, granted April 7, 2014 to two past directors were not exercised within the required option period following the directors' departure and expired. On October 16, 2014, 50,000 stock options, granted April 7, 2014 to a past employee were not exercised within the required option period following the employee's departure and expired. On October 28, 2014, 300,000 stock options, granted January 11, 2011 to a past employee were not exercised within the required option period following the employee's departure and expired. On October 28, 2014, 100,000 stock options, granted May 24, 2011 to a past employee were not exercised within the required option period following the employee's departure and expired. On October 28, 2014, 25,000 stock options, granted March 14, 2014 to a past employee were not exercised within the required option period following the employee's departure and expired. On October 28, 2014, 50,000 stock options, granted April 7, 2014 to a past employee were not exercised within the required option period following the employee's departure and expired.

During the six months ended June 30, 2015, 1,350,000 stock options granted to a past director and a past employee were not exercised within the required option period, following the director's and employees departure, and were forfeited.

SUBSEQUENT EVENTS

There are no subsequent events to report at this time.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES

Please refer to Note 2 of the Company's December 31, 2014 audited consolidated financial statements.

RISK AND UNCERTAINTIES

The Company is subject to numerous risks and uncertainties as a result of its stage of development. The following risk factors outline some of the risks that may impact the Company and its business but are not a definitive list of all risk factors associated with the Company and its business.

Development Stage Company

The Company is subject to all the risks inherent in the establishment of a new business enterprise, including the need to develop efficient systems while focusing on the development of new products. The likelihood of success of the Company must be considered in view of the problems, expenses, difficulties and delays frequently encountered in connection with the development of a new business.

Strategic and Operational Risks

Strategic and operational risks are risks that arise if the Company fails to launch its product into the market place on a profitable and timely basis or fails to raise the required capital of debt and/or equity financing for profitable operations to be achieved. The strategic opportunities or threats arise from a range of factors, which might include: (1) competitors actions, (2) regulatory requirements and (3) general economic and political conditions.

Fair Value

The carrying value of cash, accounts receivable, government remittances receivable, accounts payable and accrued liabilities do not materially differ from their fair values given their short-term to maturity. The convertible promissory note and loan payable are carried at an amortized cost using a market interest rate. As such the carrying value does not materially differ from the fair market value.

Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company has a planning and budgeting process in place by which it anticipates and determines the funds required to support normal operation requirements as well as growth and development of its Omega-3 pharmaceutical products and diagnostic. The Company coordinates this planning and budgeting process with its financing activities through the capital management process described in Note 14 of the audited consolidated financial statements for the twelve months ended December 31, 2014.

The Company's financial liabilities are comprised of its accounts payable and accrued liabilities and government remittances payable, for financial liabilities within 90 days or less of $494,721 and financial liabilities of over 90 days of $7,742,522, which includes liabilities of $6,638,767 in Convertible Promissory Notes and $302,976 of Conversion Option Derivative. In the event that Pivotal is unable to obtain additional capital over the next twelve months, there may be substantial doubt about the Company's ability to continue as a going concern and realization of assets and payment of liabilities as they become due.

Interest Rate Risk

The Company's cash and cash equivalents are held in the form of cash deposits and/or term deposits at a Canadian chartered bank. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of the financial institutions. As at June 30, 2015 and December 31, 2014 the Company has no significant exposure to interest rate risk through its financial instruments.

Foreign Currency Risk

The Company is exposed to currency risk because it makes purchases and sales transacted in U.S. dollars and Euro. At June 30, 2015, a 10% change in the average exchange rate between Canadian dollars and U.S. dollars or Euro would have resulted in a $8,700 change on reported net loss and comprehensive loss for the period.

Credit Risk

Credit risk is defined as the risk that one party to a financial instrument will cause a financial loss to the other party by failing to discharge an obligation. Substantially all the Company's cash is held with major financial institutions in Canada and management believes the exposure to credit risk with such institutions is not significant. The Company is also exposed to credit risk in the event of non-performance by customers paying outstanding trade receivables. At June 30, 2015 and December 31, 2014 no amounts due from customers were considered past due and no allowance for uncollectible amounts was considered necessary. As at June 30, 2015, one customer accounted for 98% of accounts receivable as compared to two customers at 62% and 31% as at December 31, 2014.

General and Industry Risks

The Company's financial success may be dependent upon the extent to which it can develop, market and distribute its lead product, VASCAZEN®.

Competition

The pharmaceutical/health care industry is intensely competitive in all of its phases, and the Company will compete with many companies possessing greater financial resources and technical facilities than the Company.

Additional Funding Requirement

The Company will require additional capitalization to further manufacture and market its products, and to continue protection of its intellectual property portfolio. The Company will likely need to raise additional funds to support its long-term product development and commercialization programs. The Company offers no assurance that future funding will be secured or, if secured, will be on reasonable terms.

Capital

The primary source of future funds presently available to the Company is through the sale of equity capital or the assumption of debt. There is no assurance that such sources of financing will be available on acceptable terms, if at all. If the Company seeks additional equity financing, the issuance of additional shares may dilute the interests of their current shareholders. Failure to obtain such additional financings could result in delay or indefinite postponement of the Company's strategic goals.

No History of Earnings or Dividends

To date, the Company has limited history of earnings, and there is no assurance that the Company will generate earnings. The Company has not generated significant revenues from the sale of products and accordingly has not made an operating profit. The accumulated deficit as at June 30, 2015 is $18,597,774. It is anticipated that the Company will continue to experience operating losses in the short run until significant commercial sales have been achieved. There can be no assurance that the Company will ever achieve significant revenues, profitable operations or provide a return on investment in the future. The Company has no plans to pay dividends for the foreseeable future.

Potential Profitability Depends Upon Factors Beyond the Control of the Company

The potential profitability of the Company is dependent upon many factors beyond the Company's control. Profitability also depends on the costs of operations, including costs of labor, equipment, electricity, regulatory compliance or other production inputs. Such costs will fluctuate in ways the Company cannot predict and are beyond the Company's control, and such fluctuations will impact on profitability and may eliminate profitability altogether. Additionally, events, which cause worldwide economic uncertainty, may make the raising of funds for development difficult. These changes and events may materially affect the financial performance of the Company.

Possible Volatility of Securities Prices

The market price of the Company's securities following the offering may be highly volatile, as has been the case with securities of other companies in emerging industries. Factors such as the Company's operating results and announcements by the Company or its competitors concerning technological innovations or new products may have a significant effect on the market price of the Company's securities. In addition, market prices for securities of many emerging companies have experienced wide fluctuations not necessarily related to the operating or other performance of such companies.

Key Personnel and External Collaborators

Pivotal's product development capacity will depend, to a great extent, on its ability to attract and retain highly qualified staff, as well as to establish and maintain relationships with its collaborators. The competition in this area is very intense. Pivotal's success is highly dependent upon its senior officers, its scientific personnel as well as its consultants and collaborators. The loss of key employees or collaborators, if any, could compromise the pace and success of the Company's product development, commercial and operational success.

Government Regulation

The business of the Company may be subject to government regulation, including the Health Protection Branch of Health Canada, the U.S. Food and Drug Administration ("**FDA**") and applicable health authorities in other countries, with regard to the development, testing, manufacturing and marketing of the products. Even though the Company's product will be marketed as a Medical Food, a distinct category of FDA regulated products that do not require FDA premarket approval; there are a number of strict guidelines that must be adhered to. There can be no assurance that any required regulatory approvals will be maintained and/or obtained on a timely basis or at all, or that difficulties or excessive costs will not be encountered by the Company in its efforts to secure necessary approvals, which could delay for a considerable period of time or prevent the Company from marketing its products. Regulatory authorities may impose costly requests upon the Company for additional data, the result of which may be a delay in the marketing of its products. Any such delay in obtaining or failure to obtain such approvals would adversely affect the marketing of the Company's planned products and the ability to earn product revenues.

Patents and Proprietary Technology

The Company's success will depend, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of others. Interpretation and evaluation of biotechnology patent claims present complex and often novel legal and factual questions. Accordingly, there is some question as to the extent to which discoveries and related products and processes can be effectively protected by patents. There can be no assurance that the patent applications assigned to the Company will be issued or that any issued patents will be valid and enforceable if challenged or that any patent will provide the Company with a competitive advantage. In addition, others may have filed patent applications and may have been granted patents or otherwise obtained proprietary rights to technologies potentially useful to the Company. The extent to which the Company may be required to modify its products by reason of the rights asserted by others is also unknown. There is no assurance that the Company's proprietary technology will not be circumvented through adoption of a competitive though non-infringing process or product. The cost of enforcing the Company's patent rights, if any, in lawsuits that the Company may bring against infringers or defending itself against infringement charges by other patent holders may be significant and could limit the Company's operations.

Manufacturing Capabilities

The Company is a development stage company with no existing manufacturing capabilities and is reliant upon entering into supply and manufacturing agreements with third parties for the manufacture of product. There can be no assurance that the Company will be able to manufacture or negotiate agreements to manufacture any products on a cost effective basis.

Limited Supply

There are a limited number of potential suppliers of highly purified Omega-3 for the Company's products. There can be no assurance that the Company will be able to lock up supply from these organizations for any significant length of time nor is there any assurance that the supplier will be able to supply all the oil required by the Company.

Dependence on Single Product Line

Although the Company anticipates developing other products, its operations are currently restricted to the development of its lead product, VASCAZEN®. In the event the Company is unable to market such products for any reason, it would be materially adversely affected.

Sales and Marketing

The Company has a limited history of selling, marketing and distributing its products. In order to market any of its products, the Company has established a dedicated sales force with expertise in such areas as marketing, sales and customer support in the United Sates. There can be no assurance that the sales or marketing efforts will be successful.